CBFA2T3::GLIS2融合基因阳性儿童急性巨核细胞白血病3例报告及文献复习
回顾性分析中国医学科学院血液病医院收治的3例CBFA2T3::GLIS2融合基因阳性儿童急性巨核细胞白血病(AMKL)的临床表现、遗传学特征、治疗及预后。3例患儿均达形态学完全缓解但均早期复发,中位复发时间11个月,中位总生存期16个月,提示该亚型侵袭性强、预后极差。
要点
- CBFA2T3::GLIS2融合阳性AMKL常伴CD56阳性、HLA-DR阴性免疫表型及复杂核型。
- 该亚型复发率高,中位复发时间11个月,中位总生存期16个月。
- 目前缺乏有效治疗手段,亟需探索新策略改善结局。
核心结论
- CBFA2T3::GLIS2融合基因阳性AMKL是一类侵袭性极强的亚型,复发率高、预后极差,目前尚缺乏有效治疗手段。
研究设计与样本
- 回顾性分析中国医学科学院血液病医院收治的3例CBFA2T3::GLIS2融合基因阳性AMKL患儿的临床表现、遗传学特征、治疗经过及预后,并结合国内外文献总结。
主要发现
- 3例患儿中男1例、女2例,中位发病年龄16个月(范围8~19个月),初诊时2例合并中枢神经系统白血病。
- FAB分型均为AML-M(7),免疫表型均CD56阳性、HLA-DR阴性,染色体核型均为复杂异常,其中2例涉及21号染色体三体。
- 全部患儿经化疗达形态学完全缓解,但均早期复发,中位复发时间11个月(范围7~13个月),中位总生存期16个月(范围15~47个月)。
- 1例首次移植后复发、二次移植后再次复发,现行姑息治疗;另2例复发后放弃治疗并死亡。
临床怎么用
- 对儿童AMKL应关注CBFA2T3::GLIS2融合基因检测,并结合CD56阳性、HLA-DR阴性及复杂核型识别高危亚型。
- 该亚型即使达形态学完全缓解仍易早期复发,需密切监测并探索新型治疗策略。
局限性
- 回顾性分析仅3例,样本量小。
- 单中心经验,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study retrospectively analyzed the clinical manifestations, genetic characteristics, treatment courses, and prognoses of patients with pediatric acute megakaryoblastic leukemia (AMKL) with CBFA2T3::GLIS2 fusion treated at the Institute of Hematology, Chinese Academy of Medical Sciences. Further, the diagnostic and therapeutic features of this rare AMKL subtype, in conjunction with domestic and international literature, were summarized. The patients comprised one male and two females, with a median age at onset of 16 months (range, 8-19 months). Central nervous system leukemia was present at diagnosis in two cases. All were classified as acute myeloid leukemia (AML) -M(7) according to the French-American-British classification, with immunophenotypes demonstrating CD56 positivity and human leukocyte antigen-DR negativity. All patients showed complex abnormal karyotypes, including trisomy 21 in two cases. All patients achieved morphological complete remission (CR) after chemotherapy. However, all patients experienced early relapse, with a median relapse time of 11 months (range, 7-13 months), and the median overall survival time was 16 months (range, 15-47 months). One patient relapsed after the first hematopoietic stem cell transplantation and relapsed again after a second transplantation and is currently receiving palliative care. The other two patients discontinued treatment after relapse and subsequently died. These results reveal that CBFA2T3::GLIS2 fusion-positive AMKL is a highly aggressive subtype, frequently associated with a CD56-positive, HLA-DR-negative immunophenotype, and complex karyotypes, with trisomy 21 observed in a subset of cases. This subtype is characterized by a high relapse rate and an extremely poor prognosis. At present, effective therapeutic approaches are lacking, with an urgent need to explore novel treatment strategies to improve clinical outcomes. 回顾性分析中国医学科学院血液病医院收治的3例CBFA2T3::GLIS2融合基因阳性急性巨核细胞白血病(AMKL)患儿临床表现、遗传学特征、治疗经过及预后,并结合国内外文献对该罕见类型AMKL的诊疗特点进行总结。3例患儿中男1例,女2例,中位发病年龄16(8~19)个月,初诊时2例合并中枢神经系统白血病。FAB分型均为急性髓系白血病(AML)-M(7),免疫表型均表现为CD56阳性、HLA-DR阴性,染色体核型均为复杂异常核型,其中2例涉及21号染色体三体。全部患儿经化疗均达形态学完全缓解,但均于早期复发,中位复发时间11(7~13)个月,中位总生存期16(15~47)个月。1例患儿首次移植后复发,二次移植后再次复发,现行姑息治疗;另2例复发后放弃治疗,最终死亡。结果显示,CBFA2T3::GLIS2融合基因阳性AMKL是一类侵袭性极强的亚型,常伴CD56阳性、HLA-DR阴性免疫表型及复杂核型,部分病例涉及21号染色体三体。该类患儿复发率高,预后极差。目前尚缺乏有效的治疗手段,亟需探索新的治疗策略以期改善结局。.
引用
- Lin S, Guo Y, Zhang L, et al. [Acute megakaryoblastic leukemia with CBFA2T3::GLIS2 fusion gene: 3 cases report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 41991315. doi:10.3760/cma.j.cn121090-20250814-00384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。